Eagle Pharmaceuticals
Presencia
Eagle Pharmaceuticals es una de las ...
Eagle Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización EGRX (US).
Fusión, adquisición y financiación con participación de Eagle Pharmaceuticals.
- Revelation Pharma has announced the acquisition of Eagle Pharmaceuticals (publicado el 24 de julio de 2023).
Ejecutivos
Ver el organigrama con sus 8 ejecutivos principales
Biografías más buscadas en Eagle Pharmaceuticals
- Michael Graves, Interim Executive Chairman of the Board
- Robert Glenning, Director
- Richard Edlin, Director
Recientes movimientos de ejecutivos en Eagle Pharmaceuticals
- Steven Ratoff que ha sido Non-Executive Director, ha ascendido a Non-Executive Director and Interim Chief Financial Officer (noticia publicada el 11 de marzo de 2024).
- Brian Cahill, Chief Financial Officer, ha dejado la empresa (noticia publicada el 11 de marzo de 2024).
- Scott Tarriff, President, Chief Executive Officer and Director, ha dejado la empresa (noticia publicada el 29 de noviembre de 2023).
Crear su alerta
para seguir los movimientos de los ejecutivos en Eagle Pharmaceuticals.
Farmacia
Eagle Pharmaceuticals tiene 1.867 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
- Frontier Medicines acaba de anunciar una recaudación de fondos de 80 millones de dólares. (publicado el 27 de febrero de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Eagle Pharmaceuticals
- Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation | Eagle Pharmaceuticals Investor Center
- Press Releases | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020 | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection) | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke | Eagle Pharmaceuticals Investor Center
- Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer | Eagle Pharmaceuticals Investor Center
- Eagle Pharmaceuticals and NorthShore University HealthSystem to Study Dantrolene Sodium for the Treatment of Concussion and Other Forms of Traumatic Brain Injury | Eagle Pharmaceuticals Investor Center
- Press Releases | Eagle Pharmaceuticals Investor Center
- View more press releases Close
Redes sociales sobre Eagle Pharmaceuticals
- Eagle Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Eagle Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Daniel O'Connor 
Llame a Eagle Pharmaceuticals al +1 201...
